LYEL News and Press, Lyell Immunopharma Inc. From 05/10/22

Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipeline Research highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors present...

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in ...

Gainers: Gaia (GAIA) +14%. AST SpaceMobile (ASTS) +11%. Harmonic  (HLIT) +10%. Cardlytics (CDLX) +10%. Monolithic Power Systems (MPWR) +7%. Losers: EverQuote (EVER) -15%. Varonis Systems (VRNS) -10%. Shattuck Labs (STTK) -9%. SoundHound  ...

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that two abstracts have been accepted for poster presentations at th...

Gainers: Spruce Biosciences (SPRB) +7%. ThredUp  (TDUP) +7%. Cellectis  (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats  (SEAT) -6%. Y-mAbs Therapeutic...

Lyell Immunopharma press release (NASDAQ:LYEL): Q4 net loss of $83.70M Revenue of $2.31M (-18.1% Y/Y). For further details see: Lyell Immunopharma reports Q4 results

Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipeline Clinical development commencing for two programs that incorporate Lyell’s novel reprogramming technologies SOUTH SAN FRANCISCO,...

Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...

LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the ma...

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A ...